Novo's M&A head joins Forbion as Perrigo CEO steps down over conduct concerns

Novo's senior M&A executive has left the company to take a role at Dutch investment firm Forbion.

Forbion, which manages a portfolio of biotech companies, has been active in M&A and aims to increase the value of its holdings through further transactions.

Perrigo announced that its chief executive resigned after allegations related to personal conduct, prompting a leadership transition.

Both moves highlight ongoing leadership reshuffles in the pharma and biotech sectors, which could influence future deal activity and corporate strategies.